Inclusion Criteria: Potential Subjects MUST:  Sign and date an IRB-approved written Informed Consent Form prior to initiation of any study procedures; Be an adult male or female ≥ 18 and ≤ 50 years of age; Present with limb trauma and/or planned amputation of a limb; Be candidates for a secondary nerve surgery such as Targeted Muscle Reinnervation (TMR) procedure within 6-12 months from time of amputation; Have at least one nerve end measuring greater than 4 mm and less than 7 mm in diameter after debridement and hemostasis of the proximal nerve stump; Have sufficient soft tissue available to be adequately covered by the Axoguard Nerve Cap; Be willing and able to comply with all aspects of the treatment and follow-up assessments and to return for all required study visits throughout the study duration.  Exclusion Criteria: Potential Subjects MUST NOT:  Currently undergoing or are expected to undergo treatment with chemotherapy, radiation therapy, or other known treatment that affects the growth of neural and/or vascular tissues; Have signs and symptoms of chemotherapy-induced peripheral neuropathy from previous chemotherapy; Currently use or are likely to need to use any medication listed in Appendix C during the study. Be immunosuppressed, immunocompromised or have planned immunosuppressive therapy during the duration of the study; Be pregnant, suspected of being pregnant or planning to become pregnant within 15 months; Current uncontrolled local or systemic infection as indicated by positive blood culture or other pathological indicators of infection; Be contraindicated for soft tissue implants. This includes but is not limited to any pathology that would limit the blood supply to the target area or otherwise compromise healing; Have a life expectancy of less than 15-months; Have a history of or be planning to undergo radiotherapy in the area of the end-neuroma; Have confirmed or suspected bony exostosis of the affected limb; Have insufficient perfusion of the repair site that would affect wound or tissue healing in the opinion of the investigator; Have Type 1 or Type 2 Diabetes Mellitus requiring regular insulin therapy; Active, unstable peripheral vascular disease with inaudible doppler readings or other signs of inadequate perfusion proximal to the amputation site. Have a history of idiopathic neuropathy/radiculopathy, known sciatica or chronic back pain; Documented history of centralized nerve pain that does not respond to a peripheral nerve block in the affected limb; Have a known allergy to anesthetic agents; Have a known sensitivity to porcine-derived products; Have any contraindications to MRI such as metallic implants, pacemakers, prosthetic heart valves, contrast allergy or body weight over the MRI table specific weight limitations; Be currently enrolled or have been enrolled in another interventional clinical research study within the past 30 days (at time of consent); or Be deemed unsuitable for inclusion in the study at the discretion of the Investigator.